HYSTER-YALE, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that HYSTER-YALE, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.77B | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $4.31B | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $4.12B | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $3.55B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $3.08B | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $719.60M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $652.40M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $654.40M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $785.70M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $834.80M | Feb 24, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $632.80M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $895.50M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $785.60M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $433.90M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $363.40M | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $121.70M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $103.40M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $103.60M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $136.70M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $141.20M | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.10M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $142.30M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $125.90M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | ($74.10M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($173.00M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $13.10M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $5.10M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $3.60M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $15.30M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $3.40M | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.10M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $244.80M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $208.70M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | ($39.10M) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($152.30M) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | $13.70M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $7.30M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $8.70M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $20.20M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $8.10M | Feb 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.20M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $135.90M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $119.70M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $100.70M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $108.30M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $100.50M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $115.30M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $110.90M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $104.50M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $107.00M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $616.50M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $628.10M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $576.90M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $473.00M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $450.10M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $415.50M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $487.90M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $458.20M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $428.50M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $394.60M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.10M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $170.70M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $150.70M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $40.60M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | ($253.50M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $166.90M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $76.70M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $67.60M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $164.70M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($48.90M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.50M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $47.80M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $35.40M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $28.80M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $44.30M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $51.70M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $49.70M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $38.80M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $41.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $42.70M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.02B | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $2.03B | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $2.08B | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $2.03B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $1.97B | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.86B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.85B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.74B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.65B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $1.29B | Feb 26, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.53B | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $1.54B | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $1.67B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.80B | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.59B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.21B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.27B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.18B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.08B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $816.70M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $472.00M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $475.10M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $389.90M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $204.40M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $357.10M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $616.90M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $544.30M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $527.40M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $565.50M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $463.80M | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.70M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $54.60M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $53.30M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $51.30M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $56.50M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $114.70M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $106.70M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $108.30M | Feb 24, 2021 |
| FY2018 | Jun 1, 2018 | $55.10M | Feb 26, 2019 |
| FY2019 | Dec 31, 2017 | $59.10M | Feb 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $289.10M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $374.60M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $256.30M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $152.70M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $248.60M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $443.20M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $427.40M | Feb 24, 2021 |
| FY2019 | Jan 1, 2019 | $408.70M | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $407.30M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $389.10M | Feb 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $65.50M | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $151.40M | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $64.60M | Feb 28, 2022 |
| FY2021 | Dec 31, 2018 | $83.70M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $220.10M | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $43.20M | Feb 25, 2020 |
| FY2018 | Dec 31, 2015 | $155.10M | Feb 26, 2019 |
| FY2017 | Dec 31, 2014 | $111.40M | Feb 27, 2018 |
| FY2016 | Dec 31, 2013 | $175.70M | Feb 28, 2017 |
| FY2015 | Dec 31, 2012 | $151.30M | Feb 17, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $473.40M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $417.30M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $466.70M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $523.30M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $490.30M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $260.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $266.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $284.20M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $270.90M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $184.50M | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 8 | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (10) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 8 | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | (10) | Feb 27, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | 0 | Feb 19, 2013 |
| FY2012 | Dec 31, 2011 | 100 | Feb 19, 2013 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.40M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $24.00M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $22.30M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | $21.80M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $21.60M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $21.30M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $21.00M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $20.40M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $19.80M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $19.20M | Feb 26, 2019 |